Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 24 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)

Next Previous
Trial Profile

PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 24 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zelicapavir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms RSVPED
  • Sponsors Enanta Pharmaceuticals

Most Recent Events

  • 17 Nov 2025 According to an Enanta Pharmaceuticals media release, Company presented data from this study at the Infectious Diseases Society of America (IDSA) 2025 Conference (IDWeek™).
  • 07 Oct 2025 According to an Enanta Pharmaceuticals media release, data from this trial for zelicapavir, will be presented at IDWeek 2025 being held October 19 - 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia.
  • 08 Jul 2025 Given protocol has been amended as above-1) Primary endpoints has been amended. 2) Actual number of patients has been changed from 96 to 99.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top